Edwards Lifesciences Corporation logo

Edwards Lifesciences Corporation

EW

NYSEHealthcareMedical - Devices

最新資料

US$90.91

+US$1.01 · +1.12%

8月24日 下午3:10 ET

EW公司概覽

盤中時間採用ET。市場資料可能有所延遲。

GoAI 研究快照

簡明呈現最新可用的模型資訊。

2026年7月10日

GoAI評分

Hold

Wait — insufficient conviction to act

估值

34

Expensive

動能

55

Neutral

情緒

65

Bullish

風險韌性

79

Moderate Risk

完整 GoAI 研究

繼續查看更深入的依據、催化因素和風險。

看完整研究

人工智慧產生的上下文僅供參考,並非投資建議。

公司概況

公司網站

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

產業
Medical - Devices
部門
Healthcare
總部
US
執行長
Bernard J. Zovighian
上市以來
2000年3月27日
僱員
16,000

市場位置

成交量
148.82萬
0.3× 平均值
平均成交量
488.62萬
日均成交量
市值
522.83億 USD
貝塔
0.85
市場參考 1

財務數據

財務快照

最近十二個月

財務健康

奧特曼 Z 分數
12.71
皮奧特羅斯基 F 分數
6 共 9 個

財報歷史與展望

最新財年每股收益
1.83
2025會計年度 · 年增-73.74%
最新財年收入
60.68億 USD
2025會計年度 · 年增+11.55%

年度每股收益趨勢

已公布業績及可用的市場共識預估。

已公布市場共識預估
年度每股收益趨勢7.485.433.371.3221會計年度22會計年度23會計年度24會計年度25會計年度

年度營收趨勢

已公布業績及可用的市場共識預估。

已公布市場共識預估
年度營收趨勢61.73億57.5億53.27億49.04億21會計年度22會計年度23會計年度24會計年度25會計年度

EW同業公司

持有EW的ETF

報告持有此股票曝險的交易所交易基金。

繼續GoAI的研究

在 GoAI 中研究EW

research.disclaimer